Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography.
Nick S NurmohamedAlexander R van RosendaelIbrahim DanadQuyen Ngo-MetzgerPam R TaubKausik K RayGemma FigtreeMarc P BonacaJudith HsiaFatima RodriguezAlexander T SandhuKoen NiemanJames P EarlsUdo HoffmannJeroen J BaxJames K MinDavid J MaronDeepak L BhattPublished in: European heart journal (2024)
Clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual's complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE). Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and characterization. The accuracy of CCTA for quantifying stenosis and atherosclerosis has been validated in numerous multicentre studies and has shown consistent incremental prognostic value for MACE over the clinical risk spectrum in different populations. Serial CCTA studies have advanced our understanding of vascular biology and atherosclerotic disease progression. The direct disease visualization of CCTA has the potential to be used synergistically with indirect markers of risk to significantly improve prevention of MACE, pending large-scale randomized evaluation.
Keyphrases
- coronary artery disease
- cardiovascular events
- cardiovascular disease
- coronary artery
- computed tomography
- risk factors
- double blind
- randomized controlled trial
- magnetic resonance imaging
- clinical trial
- emergency department
- image quality
- type diabetes
- study protocol
- cross sectional
- magnetic resonance
- risk assessment
- phase iii
- human health
- contrast enhanced
- dual energy
- adverse drug
- phase ii
- pet ct
- drug induced
- transcatheter aortic valve replacement